CliffBio
biologic

Abrysvo

Respiratory Syncytial Virus Vaccine

Loss of exclusivity—loss of exclusivity
CompanyPfizer →See this company's full patent-cliff portfolio

Drug detail

Brand nameAbrysvo
Active ingredientRespiratory Syncytial Virus Vaccine
Strength120UG
Dosage formInjection
RouteIntramuscular
ModalityBiologic
Marketing statusRx

More from Pfizer

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

Abrysvo patent cliff — loss of exclusivity — | CliffBio